TrialCancer science2024

Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.

Yasuo Mori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.